These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34633229)

  • 21. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.
    Baselyous Y; De Cocinis M; Ibrahim M; Kalra A; Yacoub R; Ahmed R
    Expert Opin Drug Saf; 2019 Mar; 18(3):153-161. PubMed ID: 30929580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.
    Serebruany VL; Hall TS; Atar D; Agewall S; Hyun Kim M; Geudelin B; Lomakin N; Marciniak TA
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):210-215. PubMed ID: 30192939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.
    Mukai R; Hasegawa S; Umetsu R; Nakao S; Shimada K; Uranishi H; Masuta M; Suzuki H; Nishibata Y; Nakamura M
    J Clin Pharm Ther; 2019 Apr; 44(2):285-291. PubMed ID: 30569470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction between paracetamol and lamotrigine: new insights from the FDA Adverse Event Reporting System (FAERS) database.
    Carnovale C; Mosini G; Gringeri M; Battini V; Mazhar F; Pozzi M; Clementi E; Radice S
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1323-1325. PubMed ID: 31201435
    [No Abstract]   [Full Text] [Related]  

  • 27. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
    Putzke J; Haughie S; Zou KH; Ranganna GM
    BioDrugs; 2021 May; 35(3):373-374. PubMed ID: 33860919
    [No Abstract]   [Full Text] [Related]  

  • 28. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
    Zhou Z; Hultgren KE
    JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are dizziness-related symptoms signals for suboptimal treatment of hypothyroidism? New insights from the FDA adverse event reporting system (FAERS) database.
    Carnovale C; Battini V; Mazhar F; Mosini G; Gringeri M; Vicenzi A; Clementi E; Radice S
    Eur J Clin Pharmacol; 2020 May; 76(5):733-734. PubMed ID: 31974736
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.
    Ando G; Taguchi K; Enoki Y; Yokoyama Y; Kizu J; Matsumoto K
    Biol Pharm Bull; 2019; 42(11):1799-1804. PubMed ID: 31685764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
    Qian J; Truong CB; Tanni KA
    BioDrugs; 2021 May; 35(3):375-377. PubMed ID: 33860920
    [No Abstract]   [Full Text] [Related]  

  • 35. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polypharmacy in three different spontaneous adverse drug event databases.
    Mabuchi T; Hosomi K; Yokoyama S; Takada M
    Int J Clin Pharmacol Ther; 2020 Nov; 58(11):601-607. PubMed ID: 32729825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.
    Kazerooni R; Armstrong EP
    Clin Drug Investig; 2018 Sep; 38(9):867-872. PubMed ID: 29926379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.